Co-Diagnostics (CODX)
Develops portable PCR instruments, test cups, and molecular assays.
Something off on this page? Send us feedback.
Develops molecular-diagnostics products spanning CoPrimers chemistry, laboratory PCR reagents, and the Co-Dx PCR Pro platform, designed to pair portable instruments with proprietary consumables; current revenue comes from legacy products and development grants.
Builds molecular-diagnostics products around patented CoPrimers chemistry, including legacy laboratory PCR reagents and tests, plus the Co-Dx PCR Pro platform: a portable real-time PCR instrument, single-use test cups, software, and disease-specific assays. Research, engineering, assay development, and initial manufacturing are based in Utah.
Plans to generate recurring demand from test cups and assays alongside instrument placements, while selling existing products and receiving development grants. India is served through the CoSara joint venture and other South Asian markets; CoMira is being developed for Saudi Arabia and other MENA markets. PCR Pro requires regulatory clearance before U.S. diagnostic sale, and commercialization depends on clinical studies, local regulation, manufacturing partnerships, and adoption.
Company facts
Target rangeAs of Sep 2, 2026
Latest analyst notes
No analyst notes in the last 24 months.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $3.6M · Total debt $1.8M · Total assets $16.6M · Shareholders' equity $12.7M
- Revenue
- $166.1K
- Operating income
- −$6.2M
- Net income
- −$6.3M
No dividends on record.
| Institutions14 holders · as of Mar 31, 2026 | 0.79% | 49.2K shares | |
| Insiders8 holders · as of May 27, 2026 | 1.67% | 104.3K shares | |
| Strategic holders1 holder · as of Aug 14, 2026 | 8.95% | 559.7K shares | |
| Otherremainder | 88.59% | 5.54M shares |
6.25M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Two share counts disagree (6.25M in the company's Sep 3, 2026 report, 1.12M elsewhere); stakes use the report.
A stock split fell inside the quarter, so quarter-on-quarter changes are not shown.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Armistice Capital, LLCStrategic | 8.95% | 559,706 | 13Gfiled Aug 14, 2026 ↗ |
Private Advisory Group LLCInstitution | 0.66% | 41,387 | 13Fas of Mar 31, 2026 |
Dwight H. EganInsiderdirector, officer: Chief Executive Officer | 0.45% | 27,893 | Form 4filed May 27, 2026 ↗ |
Brian Lee BrownInsiderofficer: Chief Financial Officer | 0.36% | 22,379 | Form 4filed May 27, 2026 ↗ |
Edward L. MurphyInsiderdirector | 0.18% | 11,084 | Form 4filed May 27, 2026 ↗ |
| See all 25 → | |||
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more · Form 4 — an insider's transaction report
Insider tradesForm 4
No open-market trades in the last 12 months.
